HK Stock Market Move | HBM HOLDINGS-B(02142) rose by over 7% again. The company has officially appointed a Chief Strategy Officer to expand global business.

HBM HOLDINGS-B (02142) rose by over 7%, with a cumulative increase of over 580% since the beginning of December 24th. As of the time of publication, it rose by 6.69%, closing at 7.97 Hong Kong dollars, with a turnover of 44.71 million Hong Kong dollars. On the news front, Hepalink appointed Michael D. Patten as Chief Strategic Officer. Michael will be based in the United States and report directly to the company's founder, chairman and CEO Jing-Song Wang. During his tenure as Chief Strategic Officer, Michael will be responsible for formulating and coordinating Hepalink's global business development and development strategies, managing, operating and strengthening the company's global strategic partner network and ecosystem, focusing on high-potential overseas markets outside of China, and further enhancing Hepalink's global influence. It is worth noting that Hepalink announced earlier that, according to its license agreement with Kolon Life Science on HBM9378/SKB378 and Windward Bio AG, the company has received the corresponding upfront payment, including cash payment and equity in Windward Bio's parent company. The receipt of this upfront payment will further enhance the company's cash reserves.